arsenic has been researched along with hexamethylene bisacetamide in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jing, Y; Waxman, S; Xia, L | 1 |
| Jing, Y; Lu, M; Waxman, S; Xia, L | 1 |
2 other study(ies) available for arsenic and hexamethylene bisacetamide
| Article | Year |
|---|---|
Targeted removal of PML-RARalpha protein is required prior to inhibition of histone deacetylase for overcoming all-trans retinoic acid differentiation resistance in acute promyelocytic leukemia.
Topics: Acetamides; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Butyrates; Cell Differentiation; Drug Interactions; Drug Resistance, Neoplasm; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Tretinoin; Tumor Cells, Cultured | 2002 |
The cleavage product deltaPML-RARalpha contributes to all-trans retinoic acid-mediated differentiation in acute promyelocytic leukemia cells.
Topics: Acetamides; Antineoplastic Agents; Arsenic; Blotting, Western; Cell Differentiation; Cell Line; Cycloheximide; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Leukemia, Promyelocytic, Acute; Leupeptins; Luciferases; Multienzyme Complexes; Neoplasm Proteins; Oncogene Proteins, Fusion; Plasmids; Proteasome Endopeptidase Complex; Protein Synthesis Inhibitors; Transcriptional Activation; Transfection; Tretinoin; Tumor Cells, Cultured | 2003 |